Generic Ozempic in Saskatchewan, Alberta & Manitoba — Coverage, Price & Switching (2026)

Educational only — not medical or benefits advice

This page summarizes public formulary bulletins and insurer notices about Health Canada–authorized generic semaglutide for readers in Saskatchewan, Alberta, and Manitoba. Listings and pricing rules were checked in October 2026 and change often. Flatland Health does not sell or dispense medication. Your clinician decides what’s appropriate; your pharmacist and plan decide what’s covered. Confirm both before you act.

Direct answer

Yes, generic Ozempic is on all three Prairie public drug plans. Saskatchewan (1 July 2026) and Alberta (1 July 2026) list Apo-Semaglutide and Dr. Reddy’s semaglutide as interchangeable with Ozempic under the same EDS / special-authorization criteria; Manitoba added them as EDS benefits on 1 August 2026. Coverage is for type 2 diabetes, not weight loss, and staying on brand Ozempic may cost you the difference.

Which generic semaglutide products exist in Canada

As of our October 2026 checks of Health Canada’s Drug Product Database, two generic semaglutide injections are marketed: Apo-Semaglutide Injection (Apotex; DINs 02568020 and 02568012) and Semaglutide Injection from Dr. Reddy’s (DINs 02567806 and 02567814). Both are authorized as generic equivalents of Ozempic for adults with type 2 diabetes. Sandoz and Aspen semaglutide DINs show “Approved” but not yet marketed. Our semaglutide DIN guide lists every DIN status and shows how to check yours in 60 seconds.

A generic is still prescription-only, still dispensed by a licensed pharmacy, and still a refrigerated pen. What changes is the price — and, on the Prairies, how your plan pays.

Saskatchewan vs Alberta vs Manitoba at a glance

	Saskatchewan	Alberta	Manitoba
Public listing date	1 July 2026 (SK Drug Plan Formulary)	1 July 2026 (Alberta Drug Benefit List)	1 August 2026 (Bulletin 149)
Listed as interchangeable with Ozempic?	Yes	Yes (IC grouping; some DINs may still show “under review” on iDBL)	Yes (new interchangeable categories)
How you qualify	Exception Drug Status — same criteria as Ozempic	Step therapy / special authorization, form ABC 60012 — same as Ozempic	Exception Drug Status — T2D after metformin + a sulfonylurea
Existing Ozempic approval	SK Blue Cross: updated automatically to include generics	Same criteria apply; ask your pharmacist whether your SA carries over	Ask your pharmacist
Generic pricing on brand Ozempic	Plans with generic substitution generally pay up to the lowest-cost generic	Government plans: least-cost pricing postponed (generic supply shortage). Private ABC plans: generic pricing from 17 Aug 2026 where the plan follows it	Bulletin lists generics at roughly one-third of Ozempic’s listed unit price; ask how Pharmacare reimburses your fill
Weight management covered?	No	No	No

Summary of public bulletins and insurer notices; individual plans differ. Verify with your pharmacist before your next fill.

Saskatchewan: same EDS, automatic carry-over

According to Saskatchewan Blue Cross, the generics were added to its own benefit lists in mid-May 2026 and to the Saskatchewan Drug Plan Formulary on 1 July 2026, listed as interchangeable with Ozempic and subject to Exception Drug Status criteria. Key points for Regina, Saskatoon, Moose Jaw, and Prince Albert patients:

No new paperwork if you’re already approved. Saskatchewan Blue Cross says existing Ozempic special-authorization approvals were automatically updated to include the generics.
A past “no” probably stays a “no.” The criteria didn’t change, so a request that didn’t qualify for Ozempic generally won’t qualify for the generic.
Some plan types still exclude it. Saskatchewan Blue Cross says Blue Choice, Conversion, and Guaranteed Acceptance plans don’t reimburse Ozempic or its generics because they remain EDS drugs.
Your deductible still applies. Under the SK Drug Plan your out-of-pocket depends on your family’s deductible and co-payment level. A cheaper pen can mean you reach your deductible later in the year, not that the pen is free.

New to EDS? Our Ozempic EDS in Saskatchewan walkthrough covers who qualifies and how your prescriber applies. For cash context, see Ozempic cost in Saskatchewan.

Alberta: listed, but the price switch is on hold for public plans

Alberta Blue Cross’s Pharmacy Benefact 1324 announced that generic semaglutide would join the ADBL on 1 July 2026 for type 2 diabetes, in an interchangeable grouping with Ozempic, “with the same criteria as Ozempic.” The July 2026 ADBL update lists the products under step therapy / special authorization (first line metformin, second line sulfonylureas, where insulin isn’t an option), requested on form ABC 60012.

Least-cost pricing was postponed. On 10 July 2026 Dr. Reddy’s reported a manufacturing-related shortage, so Alberta Blue Cross postponed least-cost-alternative pricing for government-sponsored plans and extended the transition period until supply stabilizes. In plain terms: for now, staying on brand Ozempic under a government plan hasn’t been made more expensive.
Private plans moved first. From 17 August 2026, Alberta Blue Cross applies generic pricing to Ozempic claims under private employer group and personal plans that follow generic pricing.
Check iDBL for your exact DIN. When we checked the interactive Drug Benefit List in October 2026, most Ozempic and generic DINs showed step therapy / special authorization, while a few newer DINs (including one Ozempic pen and the Aspen products) showed “under review.”

Calgary, Edmonton, Red Deer, and Lethbridge readers: our Ozempic cost in Alberta guide covers cash pricing and ADBL special authorization in more depth, and Wegovy in Alberta covers the weight-management side.

Manitoba: EDS benefit since August

Manitoba Health’s Bulletin 149 (effective 1 August 2026) added Apo-Semaglutide and Dr. Reddy’s Semaglutide Injection as Exception Drug Status benefits “for the treatment of type 2 diabetes in combination with metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control.” The bulletin amendment created new interchangeable categories pairing each Ozempic DIN with its generics.

Listed price gap. In that amendment, the generics are listed at about C$78 per unit versus about C$222 for Ozempic, roughly one-third. That’s a formulary list figure, not what you’ll pay at the counter.
Pharmacare is still income-based. Your annual deductible applies before Pharmacare pays, so a lower pen price mostly matters until you hit it.
Same criteria as Ozempic. Winnipeg, Brandon, Steinbach, and Thompson patients who already went through EDS for Ozempic should ask their pharmacist whether a switch needs anything new.

More detail on the process: Ozempic and Manitoba Pharmacare EDS.

Want to stay on brand Ozempic?

You usually can, but check the cost first. Both Saskatchewan Blue Cross and Alberta Blue Cross say plans with generic substitution reimburse up to the lowest-cost interchangeable product, so choosing brand can mean paying the difference. Saskatchewan Blue Cross says brand reimbursement may still be possible when the prescriber writes “No Substitution” and the pharmacy submits the right intervention code, if your plan allows it. Alberta Blue Cross’s position is that generic semaglutide is “considered equally safe and effective as Ozempic.” If you have a clinical reason to stay on brand, that conversation belongs with your prescriber.

Not Wegovy: the weight-management question

Most “generic Ozempic” searches are really about weight loss, so here’s the straight answer. The generics authorized so far are equivalents of Ozempic, authorized for type 2 diabetes. Saskatchewan Blue Cross says they will not be considered for off-label uses, including chronic weight management, and none of the three provincial listings covers weight management. Wegovy is a separate Novo Nordisk product with its own DINs and authorization. If weight management is your goal, a licensed clinician (in person or via a Health Canada–compliant telehealth service) can talk through authorized options such as Wegovy or Zepbound and what your private plan may cover. A prescription is never guaranteed, and individual results vary.

Paying cash?

If you’re not covered, generics can still lower the counter price. Third-party Canadian price trackers have reported 2026 cash quotes for generic semaglutide pens of roughly C$90–$120, versus higher brand Ozempic quotes. Treat that as illustrative: call your pharmacy with the DIN for today’s all-in price, including dispensing fee and supply. Early supply has been uneven (see Alberta’s shortage note above), so ask before you assume your pharmacy has stock. Never use a “no prescription” or “research” seller to save money; our online-buying safety guide explains why.

FAQ

Is generic Ozempic covered in Saskatchewan?

Generic semaglutide (Apo-Semaglutide and Dr. Reddy’s Semaglutide Injection) was added to the Saskatchewan Drug Plan Formulary on 1 July 2026 as interchangeable with Ozempic, under the same Exception Drug Status (EDS) criteria for type 2 diabetes. Saskatchewan Blue Cross says existing Ozempic special-authorization approvals were updated automatically to include the generics, and that the generics are not considered for chronic weight management. Your share still depends on your Drug Plan deductible or private plan. Confirm with your pharmacist.

Is generic semaglutide on the Alberta Drug Benefit List?

Yes. Effective 1 July 2026, Apo-Semaglutide and Dr. Reddy’s semaglutide were added to the Alberta Drug Benefit List for type 2 diabetes, listed in an interchangeable grouping with Ozempic and covered through the same step therapy / special authorization criteria (form ABC 60012). Alberta Blue Cross reported a Dr. Reddy’s supply shortage in July 2026, so least-cost-alternative pricing was postponed for government-sponsored plans; private Alberta Blue Cross plans that follow generic pricing began applying it on 17 August 2026. Check the iDBL or ask your pharmacist for current status.

Is generic Ozempic covered by Manitoba Pharmacare?

Manitoba Bulletin 149 (effective 1 August 2026) added Apo-Semaglutide and Dr. Reddy’s Semaglutide Injection as Exception Drug Status benefits for type 2 diabetes when metformin plus a sulfonylurea has not achieved adequate control, and created interchangeable categories with Ozempic. The bulletin lists the generics at roughly one-third of Ozempic’s listed unit price. Pharmacare is income-based, so your deductible still applies. Confirm current status with your pharmacist.

Is generic Ozempic the same as Wegovy?

No. The generic semaglutide products authorized in Canada so far are generic equivalents of Ozempic, authorized for adults with type 2 diabetes. Wegovy is a separate Novo Nordisk product authorized for chronic weight management, with its own DINs. Saskatchewan Blue Cross says the generics will not be considered for off-label uses such as weight management. Any decision about using a product outside its authorized use belongs to a licensed clinician, and coverage is unlikely.

Can I stay on brand-name Ozempic after generics are listed?

Usually yes, but you may pay more. Saskatchewan Blue Cross and Alberta Blue Cross both say plans with generic pricing reimburse up to the lowest-cost interchangeable product, so choosing brand Ozempic can mean paying the difference unless your prescriber writes “No Substitution” and your plan honours it. Alberta government-sponsored plans had least-cost pricing postponed because of a generic supply shortage. Ask your pharmacist what your plan pays before your next fill.

Sources (re-check before you act)

Compare Prairie-serving providers → GLP-1 guide

Informational eligibility quiz Felix details May be affiliate Maple details May be affiliate